In 2025, AI agents became central to artificial intelligence progress, enabling systems to use tools and act autonomously. From theory to everyday applications, they transformed human interactions with large language models. Yet, they also brought challenges like security risks and regulatory gaps.
In 2025, the concept of AI agents became concrete for developers and consumers. According to Anthropic, these are large language models capable of using software tools and taking autonomous action. This shift began in late 2024 with Anthropic's release of the Model Context Protocol, which standardized connections between large language models and external tools.
In January 2025, the open-weight DeepSeek-R1 model disrupted markets and intensified global competition. It was followed by releases from major U.S. labs like OpenAI, Anthropic, Google, and xAI, while Chinese firms including Alibaba, Tencent, and DeepSeek expanded the open-model ecosystem, with Chinese models downloaded more than American ones.
In April, Google introduced the Agent2Agent protocol for agent-to-agent communication, designed to work alongside the Model Context Protocol. By year's end, both Anthropic and Google donated these protocols to the Linux Foundation as open standards.
By mid-2025, 'agentic browsers' emerged, such as Perplexity’s Comet, Browser Company’s Dia, OpenAI’s GPT Atlas, and others, transforming browsers from passive interfaces to active participants in tasks like booking vacations.
Workflow builders like n8n and Google’s Antigravity lowered barriers for creating custom agent systems. However, in November, Anthropic disclosed misuse of its Claude Code agent in automating parts of a cyberattack, highlighting risks for malicious activities.
Key 2025 challenges included benchmarks for composite agent systems, governance via the Linux Foundation's new Agentic AI Foundation, debates on model sizes favoring specialized ones for tasks, and socio-technical issues like energy grid strains, job displacement, security vulnerabilities from indirect prompt injections, and limited U.S. regulation compared to Europe and China.
